Multiple peptide systems, including neuropeptide Y, leptin, ghrelin, and others, are involved with the control of food intake and body weight. The peptide LENSSPQAPARRLLPP (BigLEN) has been proposed to act through an unknown receptor to regulate body weight. In the present study, we used a combination of ligandbinding and receptor-activity assays to characterize a Gα i/o proteincoupled receptor activated by BigLEN in the mouse hypothalamus and Neuro2A cells. We then selected orphan G protein-coupled receptors expressed in the hypothalamus and Neuro2A cells and tested each for activation by BigLEN. G protein-coupled receptor 171 (GPR171) is activated by BigLEN, but not by the C terminally truncated peptide LittleLEN. The four C-terminal amino acids of BigLEN are sufficient to bind and activate GPR171. Overexpression of GPR171 leads to an increase, and knockdown leads to a decrease, in binding and signaling by BigLEN and the C-terminal peptide. In the hypothalamus GPR171 expression complements the expression of BigLEN, and its level and activity are elevated in mice lacking BigLEN. In mice, shRNA-mediated knockdown of hypothalamic GPR171 leads to a decrease in BigLEN signaling and results in changes in food intake and metabolism. The combination of GPR171 shRNA together with neutralization of BigLEN peptide by antibody absorption nearly eliminates acute feeding in food-deprived mice. Taken together, these results demonstrate that GPR171 is the BigLEN receptor and that the BigLEN-GPR171 system plays an important role in regulating responses associated with feeding and metabolism in mice.
Multiple peptide systems, including neuropeptide Y, leptin, ghrelin, and others, are involved with the control of food intake and body weight. The peptide LENSSPQAPARRLLPP (BigLEN) has been proposed to act through an unknown receptor to regulate body weight. In the present study, we used a combination of ligandbinding and receptor-activity assays to characterize a Gα i/o proteincoupled receptor activated by BigLEN in the mouse hypothalamus and Neuro2A cells. We then selected orphan G protein-coupled receptors expressed in the hypothalamus and Neuro2A cells and tested each for activation by BigLEN. G protein-coupled receptor 171 (GPR171) is activated by BigLEN, but not by the C terminally truncated peptide LittleLEN. The four C-terminal amino acids of BigLEN are sufficient to bind and activate GPR171. Overexpression of GPR171 leads to an increase, and knockdown leads to a decrease, in binding and signaling by BigLEN and the C-terminal peptide. In the hypothalamus GPR171 expression complements the expression of BigLEN, and its level and activity are elevated in mice lacking BigLEN. In mice, shRNA-mediated knockdown of hypothalamic GPR171 leads to a decrease in BigLEN signaling and results in changes in food intake and metabolism. The combination of GPR171 shRNA together with neutralization of BigLEN peptide by antibody absorption nearly eliminates acute feeding in food-deprived mice. Taken together, these results demonstrate that GPR171 is the BigLEN receptor and that the BigLEN-GPR171 system plays an important role in regulating responses associated with feeding and metabolism in mice.
proSAAS | NPY/AgRP | neuroendocrine peptide | deorphanization | orexigenic N europeptides are the largest class of chemical messengers with more than 100 known neuropeptides that function in cell-cell signaling. A number of neuropeptides contribute to the regulation of feeding and body weight, including well-established peptides such as neuropeptide Y (NPY) and agouti gene-related peptide (AgRP). Ablation of hypothalamic NPY/AgRP neurons causes a dramatic reduction in body weight (1) , and selective activation of these neurons drives a robust feeding behavior in mice (2) . However, knockout of either NPY or AgRP does not significantly alter body weight or feeding (3), leading to the hypothesis that additional factors in these neurons contribute to feeding/body weight regulation (4) . ProSAAS-derived peptides (Fig. 1A) are logical candidates for this control because they are among the most abundant peptides present in mouse hypothalamus (5) (6) (7) and are greatly enriched in the AgRP/NPY neurons of the arcuate nucleus (8) . ProSAASderived peptides exhibit activity-dependent release from hypothalamic neurons (9) . Transgenic overexpression of proSAAS leads to an increase (10) and proSAAS knockout leads to a decrease in body weight (11) . Finally, immunoneutralization of two proSAASderived peptides, AVDQDLGPEVPPENVLGALLRV and LENSSPQAPARRLLPP (PEN and BigLEN), from the hypothalamus results in reduced feeding (8 (Fig. 1E) , suggesting that the hypothalamic BigLEN receptor is a Gα i/o -coupled receptor. Consistent with this idea, BigLEN treatment led to a significant decrease in adenylate cyclase activity (Fig. 1F ). Neuro2A neuroblastoma cells express a BigLEN receptor with properties similar to those of the hypothalamic receptor. Membranes from
Significance
The mechanism by which vertebrate animals control their body weight is a complex process involving a variety of molecules that regulate feeding and metabolism. Some of these molecules are neuropeptides that bind to specific receptors in feeding centers of the brain. One of the most abundant peptides in brain, LENSSPQAPARRLLPP (named BigLEN), has been proposed to function as a neuropeptide involved in regulating body weight, but the receptor through which this peptide acts had not been identified. We screened candidate receptors and found one, G protein-coupled receptor 171 (GPR171), that is activated by BigLEN. Additional studies showed that the BigLEN-GPR171 system plays an important role in regulating feeding and metabolism in mice. Thus, GPR171 is a potential target for developing antiobesity drugs.
Neuro2A cells exhibited specific [
125 I]Tyr-BigLEN binding ( Fig.  1G ) and signaling with BigLEN as evidenced by the dose-and time-dependent increases in ERK1/2 phosphorylation ( Fig. S1 A  and B) . Treatment of Neuro2A cells with BigLEN leads to a robust increase in neurite outgrowth that is blocked by pertussis toxin (Fig. 1H) , consistent with previous findings that activation of Gα i/o -coupled receptors induces neuritogenesis in Neuro2A cells (12) (13) (14) (15) . Together these results suggest the presence of a Gα i/o -coupled receptor in hypothalamus and Neuro2A cells that is activated by BigLEN.
Identification of GPR171 as the BigLEN Receptor. We searched a GPCR expression database for orphan GPCRs that were enriched in hypothalamus (16) and Neuro2A cells (17) . Using the Allen Brain Atlas (18), we winnowed the list of candidates by examining their expression in the ventral hypothalamus and identified 50 hypothalamic orphan GPCRs. This list of candidates was matched against a list of orphan GPCRs expressed in Neuro2A cells (17) . The top four orphan receptors (GPR19, GPR108, GPR165, and GPR171) were selected for further screening using a cell-based Ca +2 -release assay. Epitope-tagged orphan GPCRs were expressed in CHO cells along with a promiscuous chimeric G 16/i3 protein, and receptor activation-mediated increases in intracellular Ca +2 levels were monitored using Fluo-4NW. Of the GPCRs tested, only GPR171 produced an increase in intracellular Ca +2 with BigLEN ( Fig. 2 A and B) . This response was similar in amplitude and duration to the response to ATP, a positive control which stimulates an endogenous receptor in CHO cells. No effect was observed when the cells expressing the GPR171 receptor were treated with LittleLEN or a control peptide (Fig. 2 A and B) .
GPR171 (also known as H963) is highly conserved among mice, rats, and humans (Fig. S2) . It belongs to the P2Y-like family of receptors (19) (20) (21) (22) , being most similar in amino acid sequence to the free fatty acid and dicarboxylic acid receptors (Fig. 2C) . Although it is in the P2Y-like family, GPR171 is not activated by a variety of carboxylic acids (Fig. 2D) . Treatment of BigLEN with trypsin did not eliminate activity in the intracellular Ca +2 assay (Fig. 3A) ; this treatment converts BigLEN into LittleLEN-Arg and the C-terminal peptide Leu-Leu-Pro-Pro (L2P2). When L2P2 alone was tested, it was able to activate GPR171 (Fig. 3A) and displace radiolabeled BigLEN from rat hypothalamic membranes with an EC 50 of 76 nM, whereas a shorter peptide, LPP did not displace radiolabeled BigLEN binding (Fig. 3B) . L2P2 treatment caused a dose-dependent increase in GTPγS binding to hypothalamic membranes ( Fig. 3C ) and a dose-dependent decrease in adenylate cyclase activity (Fig. 3D ). Taken together, these results indicate that BigLEN binds to GPR171 through its C-terminal region and that the four C-terminal residues are necessary and sufficient to activate GPR171. The expression of GPR171 siRNA in Neuro2A cells led to a reduction in GPR171 protein levels ( Fig. 4A ) and a decrease in BigLEN-mediated signaling (Fig. 4B ). GPR171siRNA had no effect on signaling mediated by LittleLEN or Deltorphin II (a δ-opioid receptor agonist) (Fig. 4B) . Furthermore, GPR171siRNA expression decreased neurite outgrowth in Neuro2A cells under basal conditions as well as after BigLEN or L2P2 treatment (Fig.  4C ). The expression of GPR171 shRNA (using a lentiviral expression system) also decreased GPR171 protein levels ( In comparison, overexpression of GPR171 led to an increase in BigLEN binding (Fig. 4D) . Pretreatment with an antibody to GPR171 (but not to an unrelated antibody) led to reduced GTPγS binding to hypothalamic membranes in response to BigLEN and L2P2 (Fig. 4F ). Taken together, these results suggest that GPR171 is a receptor for BigLEN in both the hypothalamus and Neuro2A cells.
Distribution of GPR171 in Brain and Regulation of Expression. Immunohistochemical analysis shows that GPR171 is highly expressed in mouse hypothalamus, including the arcuate nucleus, paraventricular nucleus (PVN), and dorsomedial hypothalamus ( the presence of GPR171 and BigLEN within the arcuate nucleus (Fig. S4C ) as well as in the PVN and other brain regions. The presence of GPR171 protein and mRNA in the PVN is consistent with the previous finding that medial parvocellular neurons respond electrophysiologically to exogenous BigLEN (8) . The intensity of GPR171 staining in the arcuate nucleus is higher in mice lacking BigLEN (i.e., proSAAS-KO mice) than in WT controls (Fig. S4D) . Similarly, hypothalamic membranes of proSAAS-KO mice have significantly elevated BigLEN binding (1.3 ± 0.03 pmoles/mg in WT and 1.8 ± 0.06 pmoles/mg in proSAAS-KO mice) and G protein signaling (165% in WT and 175% in proSAAS-KO mice). These results suggest a compensatory increase in GPR171 expression in the absence of BigLEN, consistent with studies of other receptor systems that found upregulation of the receptor in the absence of neurotransmitters (24) . Collectively, these results support the hypothesis that the BigLEN-GPR171 system modulates the activity of neurons in the ventral hypothalamus.
Knockdown of GPR171 Affects Feeding Behaviors and Metabolism in
Mice. GPR171 shRNA lentivirus injected into the third ventricle substantially reduced the levels of GPR171 mRNA in the ventral hypothalamus (Fig. 5A) . Following a 2-wk recovery period, body weights were similar in the mice injected with control shRNA (24.9 ± 1.24 g) and mice injected with GPR171 shRNA (25.5 ± 0.72 g). At this time, mice were placed into the Comprehensive Laboratory Animal Monitoring System (CLAMS) unit for 4 d. Responses of both groups were lower during the day (0700-1900 h) than during the night (1900-0700 h) (Fig. S5 and Table S2 ). Both the respiratory-exchange ratio (RER) and heat production were increased in the GPR171 shRNA group. A more detailed examination of the data revealed two periods of peak responses; early night (1800-2400 h) responses were significantly higher than the late night (0300-0900 h) responses (Fig. 5 B-F and Table S3 ). During the early night, the GPR171 shRNA-knockdown mice consumed more food and water, were more active, and maintained higher levels of RER and heat production than the controls. Taken together, these results indicate that GPR171 plays a complex role in regulating feeding-associated behaviors as well as activity in mice.
The arcuate nucleus is a well-established site for the regulation of feeding behaviors (25) (26) (27) (28) (29) (30) . Because BigLEN and other proSAAS-derived peptides are highly expressed in the NPY neurons of the arcuate nucleus (8), we examined whether shRNAinduced knockdown of GPR171 would affect feeding-associated responses. Previous studies found that overexpression of pro-SAAS increased body weight in both male and female mice (10), whereas disruption of proSAAS decreased body weight in male mice (11) . In the present study, no changes in body weight were observed in male mice injected with GPR171 shRNA virus. However, in the current study body weight was measured only for 2 wk after viral injection; in previous studies the mice were followed over much longer times, and it took 7-12 wk for significant body weight changes to emerge. Moreover, overexpression of proSAAS or deletion of this gene should affect not only the levels of BigLEN but also those of other proSAAS-derived peptides, whereas shRNA-induced knockdown of GPR171 should influence only BigLEN responses.
The specific involvement of BigLEN in GPR171-mediated feeding behaviors was examined. As seen in a previous study (8) , administration of BigLEN antibodies to the third ventricle led to a significant decrease in acute feeding following an overnight fast (Fig. 5G) . This decrease in feeding was augmented further in mice treated with GPR171 shRNA, with food intake reduced by >90% compared with the control mice (Fig. 5H ). This combined effect of decreased GPR171 expression and removal of BigLEN further supports the idea that GPR171 functions as the receptor for BigLEN in vivo and that the BigLEN-GPR171 system plays a major role in regulating behaviors associated with feeding in mice. In summary, BigLEN appears to be a ligand for GPR171 based on the findings that (i) heterologous expression of GPR171 leads to high-affinity binding of and signaling by BigLEN; (ii) knockdown of GPR171 leads to reduced responses by BigLEN in the hypothalamus and in Neuro2A cells; (iii) a GPR171-specific antibody blocks BigLEN-mediated signaling; and (iv) GPR171 levels and activity are increased in the hypothalami of mice lacking BigLEN. Furthermore, the finding that feeding and metabolism are modulated by GPR171 knockdown in the ventral hypothalamus 35 S]GTPγS binding to rat hypothalamic membranes are blocked by pretreatment with the antibody to GPR171 (GPR171 Ab) but not by the antibody to endothelin-converting enzyme-2 (ECE2 Ab). *P < 0.05 vs. either No Ab or ECE2 Ab controls. Data represent means ± SE of three independent experiments in A or three independent experiments performed in triplicate in B-F. n.s., not significant. supports a role for the BigLEN-GPR171 system in regulating these functions. This idea is supported by the finding that third ventricular injections of antibodies to BigLEN affect food intake in mice that can be augmented by GPR171 knockdown and by previous studies which found that overexpression or deletion of proSAAS produces alterations in body weight (10, 11) . The identification of GPR171 as the receptor for BigLEN provides insights into these mechanisms but also may provide a target for therapeutic modulation of food intake and metabolism. binding assay in response to BigLEN, LittleLEN, or a control peptide (0-1 μM final concentration) as described (33, 34) . Details are given in SI Methods. Pertussis toxin (50 ng/mL) was added 30 min before the assay. Antibody blocking was with anti-GPR171 (5 μg) or anti-endothelin-converting enzyme-2 (5 μg) for 30 min before the assay. Similar antibody-blocking studies were not carried out with the other signaling or ligand-binding assays.
ERK1/2 Phosphorylation. CHO cells expressing GPR171 were treated with 1 μM BigLEN for 0-60 min or 0-10 μM BigLEN for 2 min. Neuro2A cells transfected with siRNA or infected with shRNA were treated with 1 μM of BigLEN (2 min), LittleLEN (5 min), or Deltorphin II (5 min). PhosphoERK1/2 was measured as described (35) (36) (37) . Details are given in SI Methods.
Determination of cAMP Levels. Membranes (2.5 μg) were pretreated with 40 μM forskolin for 30 min followed by BigLEN or L2P2 (0-10 μM) for 30 min. cAMP levels were quantified using the HitHunter cAMP detection kit (DiscoverX). Details are given in SI Methods.
Neurite Outgrowth Assays. The effects of BigLEN or L2P2 on neurite outgrowth were measured as described (14, 34) . Pertussis toxin (15 ng/mL) treatment was overnight before ligand treatment.
Intracellular Ca +2 Responses. CHO cells expressing myc-tagged GPR19, GPR108, GPR165, or GPR171 along with Gα 16/i3 were treated without or with ligands (1 μM). Intracellular Ca +2 levels were measured using Fluo4NW as described (34, 38) . Relative units represent the percent fold change over basal levels.
Homology and Phylogenetic Analysis. The sequences homologous to GPR171 and H963 were aligned using ClustalW. A phylogenetic tree was generated using ClustalX, and the dendrogram was constructed using the TreeView algorithm. Details are given in SI Methods.
Western Blot Analysis. Lysates (30 μg protein) were subjected to Western blot analysis using rabbit anti-GPR171 (1:1,000), mouse anti-tubulin (1:20,000), anti-rabbit IRDye 800 (1:10,000), and anti-mouse IRDye 6800 antibodies (1:10,000) as described (37) . Details are given in SI Methods.
Immunohistochemistry. Coronal sections were immunostained with Alexa 488-labeled anti-BigLEN (1:5,000) and rabbit anti-GPR171 (1:1,000) antibodies, and staining was visualized with donkey anti-rabbit Cy3-conjugated antibodies (1:1,000) as described (8) .
RT-PCR. Quantitative RT-PCR was performed using sense and antisense primers for mouse GPR171 and glyceraldehyde 3-phosphate dehydrogenase (Sigma) on cDNA prepared from total RNA isolated from the ventral hypothalami of mice expressing control or lentiviral shRNA to GPR171; cDNA was prepared as described (8) . Quantitative analysis was performed using the ΔΔC T method and REST software (www.gene-quantification.de) (39) . ) administration of GPR171 lentiviral shRNA leads to a decrease in the levels of GPR171 mRNA in the mouse ventral hypothalamus. *P < 0.0001 vs. control shRNA (n = 6 per group). (B-F) Feeding-associated responses at peak response times during the late (0300-0900 h) and early (1800-2400 h) night. GPR171 shRNA mice consumed significantly more food (B), drank more water (C), and exhibited more activity (D) than controls during late night. A significant increase in RER (E) and heat production (F) were noted in the GPR171 shRNA mice relative to controls at both night time points. Data in B-F represent means ± SE of 12-16 mice per treatment condition. *P < 0.05, GPR171 shRNA vs. control for the same time point; + P < 0.05, 0300-0900 h vs. 1800-2400 h for the same treatment. Statistical analyses are provided in Table S3 water throughout the experiment. All surgical procedures and behavioral tests were conducted according to a protocol approved by the Duke University Animal Care and Use Committee.
Behavioral Testing. Two weeks after viral injections, all animals were monitored individually for 84 consecutive h in CLAMS (Columbus Instruments). Motor activity and feeding and drinking behaviors as well as O 2 intake and CO 2 output were monitored with Oxymax software, and the RER was calculated as described (40, 41) . The data from the individual parameters were examined across light and dark cycles and then were grouped into two 6-h blocks: 1800-2400 h (the first peak response period) and 0300-0900 h (the second peak response period). The results are presented as means ± SE for the different block-hours. The results for feeding, drinking, and motor activity are shown as cumulative means; RER and heat are average values. After completion of the CLAMS study, mice were killed by decapitation, and the brain was removed for biochemical assays.
Effect of BigLEN Antibodies on Feeding. Purified antibodies to BigLEN or normal rabbit IgG (5 μg/2 μL) were infused at a rate of 0.5 μL/min into the third ventricle of cannulated mice that were fasted for 12 h (during lights out), and the amount of food consumed during at various time points postinjection was measured as described (8) . Previously, it had been found that BigLEN antibodies blocked feeding, whereas administration of BigLEN peptide was without effect, presumably because of the instability of the peptide in brain for the duration of the feeding study (8) .
Statistics. For the analysis of the in vitro data, GraphPad Prism 4.0 was used; statistical significance was determined by t test or one-way ANOVA. For the analyses of CLAMS data, SPSS 20 (IBM) was used. Food intake, water consumption, motor activity, RER, and heat production were analyzed with repeated-measures ANOVA, with time as the within-subject repeated measure and treatment condition as the between-subject measure. Bonferroni corrected pair-wise comparisons were used as the post hoc test. In all cases, P < 0.05 was considered statistically significant. No animals were excluded from the data analysis. Details of the statistical analyses are given in SI Methods.
